Equities Analysts Offer Predictions for NTLA Q1 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Intellia Therapeutics in a report issued on Wednesday, March 26th. William Blair analyst M. Minter forecasts that the company will post earnings of ($1.12) per share for the quarter. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. William Blair also issued estimates for Intellia Therapeutics’ Q3 2026 earnings at ($1.28) EPS and Q4 2026 earnings at ($1.35) EPS.

Other equities research analysts have also recently issued reports about the stock. Morgan Stanley cut shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $56.00 to $11.00 in a research report on Monday, January 27th. BMO Capital Markets cut their price objective on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, January 10th. Citigroup raised their target price on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.56.

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $8.40 on Thursday. Intellia Therapeutics has a one year low of $8.11 and a one year high of $28.23. The business has a fifty day moving average price of $10.01 and a 200 day moving average price of $13.90. The company has a market cap of $869.54 million, a P/E ratio of -1.54 and a beta of 1.97.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Intellia Therapeutics in the 4th quarter valued at $25,000. Sterling Capital Management LLC increased its stake in Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock worth $37,000 after purchasing an additional 2,867 shares during the period. Whipplewood Advisors LLC purchased a new stake in Intellia Therapeutics during the fourth quarter worth about $40,000. Resona Asset Management Co. Ltd. acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth about $43,000. Finally, Jones Financial Companies Lllp boosted its stake in shares of Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after purchasing an additional 2,280 shares during the period. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.